.Forbes names the University of Florida a “New Ivy” — recognizing UF’s top-performing graduates and the university leading higher education's evolution.
news.ufl.edu/2024/04/forbes…

With a median FU up of ~5 yrs adjuvant pembro= 38% reduction in risk of death. The benefit is across subgroups (T stage etc). Subsequent therapy in 80% is relapses. The 1st +ve OS adjuvant PD1 study, making adjuvant pembro more attractive. #GU24 Toni Choueiri, MD

51 years in the making till #GU24 . OS benefit in adjuvant Renal Cancer is finally here. #KYN564

Interim analysis of ANTICIPATE phase II trial presented by Matt Galsky showed pCR of 39% in APL-1202/Tislelizimab combination vs 21% Tislelizumab alone given as NACT in MIBC for cisplatin ineligible/declining pts with an acceptable safety profile. #GU24 ASCO

#BRCAAway is still the most convincing reason to me that we should combine PARP with novel hormonal treatments — combo olaparib-abiraterone better than each monotherapy. Congrats #MahaHussain & team for this careful trial guiding #prostatecancer care. #GU24 ASCO OncoAlert

Cabo+atezo in CRPC = ⬆️ rPFS (6.3 vs 4.2 mo HR 0.65(0.50-0.84). Immature OS 0.79(0.58-1.07). RR 13 vs 4%.We know Cabo mono has activity, and PD(L)1 has failed in CRPC. Therefore, without a Cabo mono arm it’s hard to know how much atezo is adding. Great job Neeraj Agarwal, MD, FASCO 👌⭐️ #GU24

Excited for another GU ASCO in San Francisco celebrating 20 years of this excellent symposium! Great opening session in PC with talks by Dr M Hussain, Neeraj Agarwal, MD, FASCO, Dr K Hoffman and Dr C Hennequin #gu24 ASCO

Did you know prostate cancer is the most common cancer seen in men? This Men's Health Awareness Month, Dr. Pico, hematologist & oncologist Memorial Cancer Institute, discusses the importance of annual check ups & prostate cancer screenings starting at the age of 50.

👉mhs.net/cancer

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3) #ESMO2023

EV-302 data changes the game in metastatic UC. Congrats to Tom Powles for a well conducted study and great presentation, and to the entire EV-302 study team Gopa Iyer. Congrats to Andrea Apolo, M.D. for her insightful discussion. Memorial Sloan Kettering Cancer Center Michiel van der Heijden Bladder Cancer Advocacy Network

#Goosebumps #EV302 #ESMO23

Took 3 decades but a new SOC in 1L bladder cancer !!!!!! ⁦Tom Powles⁩

EV+Pembro irrespective…..WOW! 🤩

Lenvatinib and Pembrolizumab has ⬆️⬆️ activity in non-clear cell RCC. No randomised data makes patients characteristics relevant (⬆️ good risk here). I think many will adopt this as standard of care but without randomisation it’s hard to tell the extent of the benefit. #ASCO23

#GU23 Matthew Zibelman tackles the complex subject of adj therapy in #RCC
Congrats on a great talk!
OncoAlert

.Matthew Zibelman provides in depth analysis of available adjuvant data in #kidneycancer Looking across tumor types shows just how long we may have to wait to see OS. Lots of shared decision-making will be needed in the meantime. We need to inform and listen to our patients #GU23

COSMIC313 cabo/ipi/nivo vs ipi/nivo in 1st line RCC. ⬆️ FU & ⬆️ numbers show continued strong PFS signal:HR 0.74.Exploratory analysis show benefit for triplet mainly in intermediate risk .This is not due to ⬇️ drug exposure. Maybe VEGF treatment ⬇️ active in poor risk #GU23

Talapro-2 ⬆️ rPFS for talazoparib/enza in unselected CRPC with more benefit in HRR as with olaparib/abi. Titron-3 showed rucaparib alone ⬆️ rPFS, particularly in BRCAs. ATM fails to enrich again. OS not +ve yet in either. The biomarker is important for PARPi in CRPC IMO #ASCOGU23

#GU23 ASCO Much awaited data from the ph3 Propel shows continued rPFS benefits + strong trend for OS (7 month) benefit with abiraterone + olaparib vs. abiraterone in 1st line mCRPC in HRR pos & neg #prostatecancer 👇 OncoAlert PCF Science Med-IQ #MedIQGU23

Excited to be in San Francisco for GU ASCO 2023! Fantastic start, with TRITON3 and TALAPRO-2 showing promise for incorporating PARP inhibition in earlier lines of therapy for prostate cancer but no OS benefit shown yet, pending further maturation. #GU23 ASCO Memorial Cancer Institute

Patients & Survivors, Caregivers, and Healthcare Professionals, come join the Blood Cancer Conference, a FREE, in-person, educational event.

Saturday January 14th, 2023
9:00AM -2:30PM
Fort Lauderdale Marriott Harbor Beach Resort & Spa

REGISTRATION LINK: na.eventscloud.com/website/48999/

Cancer Statistics 2023 from American Cancer Society is now published in @CAonline
#OpenAccess
acsjournals.onlinelibrary.wiley.com/doi/full/10.33…
OncoAlert